var data={"title":"Nitrous oxide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitrous oxide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6651?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitrous-oxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitrous oxide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201351\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Dental Gases;</li>\n      <li>\n        General Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201344\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Surgical sedation and analgesia:</b> Concentrations of 25% to 50% nitrous oxide with oxygen. For general anesthesia, concentrations of 40% to 70% via mask or endotracheal tube. Minimal alveolar concentration (MAC), which can be considered the ED<sub>50</sub> of inhalational anesthetics, is 105%; therefore delivery in a hyperbaric chamber is necessary to use as a complete anesthetic. When administered at 70%, reduces the MAC of other anesthetics by half. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dental: Sedation and analgesia:</b> Concentrations of 25% to 50% nitrous oxide with oxygen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201347\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201345\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201330\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Supplied in blue cylinders</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201320\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201331\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Sedation, analgesia, and amnesia; principal adjunct to inhalation and intravenous general anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5977825\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201326\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Central nervous system stimulation, confusion, dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201334\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nitrous oxide or any component of the formulation; nitrous oxide should not be administered without oxygen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use is considered contraindicated in patients having undergone vitreoretinal surgery and presence of intraocular gas bubble (Lee, 2004; Fu, 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201324\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Addictive: May be associated with abuse and/or addiction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Body space volume expansion: Both compliant (eg, bowel gas, pneumothorax) and poorly compliant (eg, middle ear) body spaces may be prone to changes in volume due to nitrous oxide transfer; avoid use in pneumothorax, pneumocephalus, middle ear surgery, or bowel obstruction (Miller 2010; Ohryn 1995; Sprehn 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Prolonged use may produce bone marrow suppression; patients with vitamin B<sub>12</sub> deficiency (pernicious anemia) and those with other nutritional deficiencies (alcoholics) are at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nausea/vomiting: Occurs postoperatively in ~15% of patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurologic effects: Prolonged use may produce neurologic dysfunction; patients with vitamin B<sub>12</sub> deficiency (pernicious anemia) and those with other nutritional deficiencies (alcoholics) are at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitreoretinal surgery: Detached retina and other ocular disorders treated with vitreoretinal surgery where intraocular gas was used: Nitrous oxide can increase intraocular pressure which may result in retinal artery occlusion, ischemia, or optic nerve damage and vision loss in these patients. Nitrous oxide should not be used in patients who have had an intravitreal gas bubble unless it can be confirmed that the bubble has been completely resorbed (Fu, 2002; Lee, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Oxygen use: Oxygen should be briefly administered during emergence from prolonged anesthesia with nitrous oxide to prevent diffusion hypoxia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299770\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201327\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10086&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14191241\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrous oxide crosses the placenta in concentrations ~80% of those in the maternal plasma. The half-life in the neonate is ~3 minutes and it is quickly eliminated from neonatal lungs with the onset of breathing (Rooks, 2011). Infertility, spontaneous abortion, and congenital abnormalities have been reported following prolonged occupational exposure (Becker, 2008; Brodsky, 1986; Rooks, 2011). Adverse events are related to dose and duration of exposure and risks may be decreased with proper administration procedures (Rooks, 2011). May be used when needed for dental treatments that cannot be postponed during pregnancy; use for labor analgesia is considered acceptable (Becker, 2008; Rooks, 2011). Avoid use in pregnant women during the first two trimesters of pregnancy, those with medical conditions that increase the risk of vitamin B<sub>12</sub> deficiency,  or infertile women undergoing <i>in vitro</i> fertilization (Brodsky, 1986; Rooks, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201323\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">General CNS depressant action; may act similarly as inhalant general anesthetics by stabilizing axonal membranes to partially inhibit action potentials leading to sedation; may partially act on opiate receptor systems to cause mild analgesia; central sympathetic stimulating action supports blood pressure, systemic vascular resistance, and cardiac output; it does not depress carbon dioxide drive to breath. Nitrous oxide increases cerebral blood flow and intracranial pressure while decreasing hepatic and renal blood flow; has analgesic action similar to morphine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201333\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Inhalation: 2-5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid via lungs; blood/gas partition coefficient is 0.47 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Body: &lt;0.004% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily exhaled gases; skin (minimal amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038705\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kinox (FR);</li>\n      <li>Maxicool (IL);</li>\n      <li>Niontix (CZ, DK, FI, IS, LT, NL, NO, PT, RO, SE, SI, SK);</li>\n      <li>Nitrous EP (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Babich S and Burakoff RP, &ldquo;Occupational Hazards of Dentistry. A Review of Literature From 1990,&rdquo; <i>N Y State Dent J</i>, 1997, 63(8):26-31. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baird PA, &ldquo;Occupational Exposure to Nitrous Oxide - Not a Laughing Matter,&rdquo; <i>N Engl J Med</i>, 1992, 327(14):1026-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/1518538/pubmed\" target=\"_blank\" id=\"1518538\">1518538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker DE and Rosenberg M, &quot;Nitrous Oxide and the Inhalation Anesthetics,&quot; <i>Anesth Prog</i>, 2008, 55(4):124-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/19108597/pubmed\" target=\"_blank\" id=\"19108597\">19108597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodsky JB and Cohen EN, &quot;Adverse Effects of Nitrous Oxide,&quot; <i>Med Toxicol</i>, 1986, 1(5):362-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/3537624/pubmed\" target=\"_blank\" id=\"3537624\">3537624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo; <i>N Engl J Med</i>, 2003, 348(21):2110-24. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/12761368/pubmed\" target=\"_blank\" id=\"12761368\">12761368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen EN, Gift HC, Brown BW, et al, &ldquo;Occupational Disease in Dentistry and Chronic Exposure to Trace Anesthetic Gases,&rdquo; <i>J Am Dent Assoc</i>, 1980, 101(1):21-31. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/6930434/pubmed\" target=\"_blank\" id=\"6930434\">6930434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunning DG, McFarland K, and Safarik M, &ldquo;Nitrous-Oxide Use. II. Risks, Compliance, and Exposure Levels Among Nebraska Dentists and Dental Assistants,&rdquo; <i>Gen Dent</i>, 1997, 45(1):82-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/9171486/pubmed\" target=\"_blank\" id=\"9171486\">9171486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fu AD, Mcdonad HR, Elliot D, et al. Complications of general anesthesia using nitrous oxide in eyes with pre-existing gas bubbles. <i>Retina.</i> 2002;22:569-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/12441721/pubmed\" target=\"_blank\" id=\"12441721\">12441721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard WR, &ldquo;Nitrous Oxide in the Dental Environment: Assessing the Risk, Reducing the Exposure,&rdquo; <i>J Am Dent Assoc</i>, 1997, 128(3):356-60. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/9066222/pubmed\" target=\"_blank\" id=\"9066222\">9066222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnsen KG, &ldquo;Nitrous Oxide Safety,&rdquo; <i>J Am Dent Assoc</i>, 1997, 128(8):1066-7. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee EJK. Use of nitrous oxide causing severe visual loss 37 days after retinal surgery. <i>Br J Anaesthes.</i> 2004;93(3):464-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/15220168/pubmed\" target=\"_blank\" id=\"15220168\">15220168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Nitrous Oxide in the Dental Office. ADA Council on Scientific Affairs; ADA Council on Dental Practice,&rdquo; <i>J Am Dent Assoc</i>, 1997, 128(3):364-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/9066223/pubmed\" target=\"_blank\" id=\"9066223\">9066223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohryn M. Tympanic membrane rupture following general anesthesia with nitrous oxide: A case report. <i>AANA J</i>. 1995;63(1):42-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/7762371/pubmed\" target=\"_blank\" id=\"7762371\">7762371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petersen JK, &ldquo;Nitrous Oxide Analgesia in Dental Practice,&rdquo; <i>Acta Anaesthesiol Scand</i>, 1994, 38(8):773-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/7887096/pubmed\" target=\"_blank\" id=\"7887096\">7887096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quarnstrom F, &ldquo;Nitrous Oxide,&rdquo; <i>J Am Dent Assoc</i>, 1997, 128(6):690, 692. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/9188225/pubmed\" target=\"_blank\" id=\"9188225\">9188225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rooks JP, &quot;Safety and Risks of Nitrous Oxide Labor Analgesia: A Review,&quot; <i>J Midwifery Womens Health</i>, 2011, 56(6):557-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/22060215/pubmed\" target=\"_blank\" id=\"22060215\">22060215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowland AS, Baird DD, Weinberg CR, et al, &ldquo;Reduced Fertility Among Women Employed as Female Dental Assistants Exposed to High Levels of Nitrous Oxide,&rdquo; <i>N Engl J Med</i>, 1992, 327(14):993-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/1298226/pubmed\" target=\"_blank\" id=\"1298226\">1298226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuyt HC, Brakel K, Oostendorp SG, et al, &ldquo;Abortions Among Dental Personnel Exposed to Nitrous Oxide,&rdquo; <i>Anaesthesia</i>, 1986, 41(1):82-3. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/3946781/pubmed\" target=\"_blank\" id=\"3946781\">3946781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprehn M, Faber T, Osgaard O. Life-threatening tension pneumocephalus after nitrous oxide anaesthesia. <i>Anaesthesia</i>. 1992 Feb;47(2):174. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanchyk A and Tanchyk A. The absolute contraindication for using nitrous oxide with intraocular gases and other dental considerations associated with vitreoretinal surgery. <i>General Dentistry.</i> 2013;61(6):6-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/24064175/pubmed\" target=\"_blank\" id=\"24064175\">24064175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Nitrous Oxide and Fertility, Part I,&rdquo; <i>Gen Dent</i>, 1993, 41(2):122-3. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/8330725/pubmed\" target=\"_blank\" id=\"8330725\">8330725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Nitrous Oxide and Fertility, Part II,&rdquo; <i>Gen Dent</i>, 1993, 41(3):212, 214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/8243958/pubmed\" target=\"_blank\" id=\"8243958\">8243958</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10086 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201351\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201344\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F201347\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201345\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201330\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201320\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201331\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5977825\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201326\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201334\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201324\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299770\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201327\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14191241\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201323\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201333\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038705\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10086|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitrous-oxide-patient-drug-information\" class=\"drug drug_patient\">Nitrous oxide: Patient drug information</a></li></ul></div></div>","javascript":null}